Nieuws


Beste Student Startup 2018 van de Minor Entrepreneurship

Geplaatst op

Op 1 februari j.l. won startup FirstFloor deze mooie prijs.

FirstFloor is bezig met een automatisch computersysteem waarin je zelf componenten kunt verslepen en plaatsen, zodat je een eigen platform kan bouwen. ‘Met ons idee willen we anderen helpen om van hun bedrijf een groot succes te maken’, vervolgt Floor. ‘Het is heel divers werk, omdat elk bedrijf zijn eigen idee heeft. Dit maakt het erg leuk om met verschillende bedrijven samen te werken.’

Met FirstFloor wonnen ze de eerste prijs voor Beste Student Startup tijdens de pitchfinale van de UvA-minor entrepreneurship. Ze moesten samen met zeven andere teams hun startup presenteren aan drie juryleden die zelf ondernemen. Als eerste prijs kregen ze duizend euro, waarmee ze nu serieuze stappen kunnen ondernemen.

Bekijk het videoverslag van de DemoDay:




Vote for Erik Boer!

Geplaatst op

ACE director Erik Boer was nominated for the #SuDSummit Toekomstmakers50! Want to cast your vote?
You can do that right here --> https://www.startupdeltasummit.com/toekomstmakers50.

The StartupDelta Summit (April 19, 2018) brings together key players of the Dutch startup ecosystem. Tickets are available on the website.


ACE Incubation Program, sign up now!

Geplaatst op

Learn how to build your science or tech company!
Do you dream of starting your own company but don’t know where to begin? Join the ACE Incubation Program. ACE helps founders build their startup with 12 weeks of training and support by leading mentors and business coaches. Sign up for our upcoming program (starts April 9).
The Incubation program is exclusively designed for MSc students, researchers & industry experts. ACE provides the resources to build and grow your startup. Based within Amsterdam Science Park’s startup community at Startup Village, ACE’s workshops take place within the heart of innovation.
Apply until March 18 at www.ace-incubator.nl/apply or email yulia@ace-incubator.nl with questions.


Kajsa Ollongren and Constantijn van Oranje will open Amsterdam Venture Studios on September 29th

Geplaatst op

The Amsterdam Venture Studios (AVS) offer science and high-tech based startups access to incubators at the Amsterdam campuses. On Friday 29 September Kajsa Ollongren and Constantijn van Oranje will jointly open the first four Venture Studio locations at Amsterdam Science Park, VU Campus, AHTC (AMC) and Amstelcampus.

https://ace-incubator.nl/venture-vibes/


AUP geeft politieke biografie van Angela Merkel uit

Geplaatst op

De politieke biografie van Angela Merkel komt nieuw binnen in de besteller top 60 op nummer 56!
http://debestseller60.nl/

https://www.trouw.nl/cultuur/de-biografie-van-angela-merkel-laat-zien-dat-zij-het-geweten-van-de-westerse-wereld-is~aab461cd/

Zij bedwong de eurocrisis, maar lukt het haar Europa net zo doortastend bij elkaar te houden? De politieke biografie van Angela Merkel door Michèle de Waard verscheen op 24 augustus bij AUP. Angela Merkel is de ongekroonde leider van Europa. 'Kanselier van de vrije wereld' noemde TIME haar zelfs. Voor haar betekent vrijheid verantwoordelijkheid nemen: principieel waar het vereist is, flexibel als het nodig is. Standvastig werkt zij aan een economisch sterk én sociaal Europa. Ze hield de eurozone bij elkaar en koos voor een gewaagde aanpak van de vluchtelingenproblematiek. 'Wir schaffen das' was haar credo. Merkels verhaal is ook het verhaal van Duitsland dat na de hereniging zijn tweede kans gebruikt om de waarden van Europa en de Europese samenwerking te verstevigen. Overtuigend beschrijft Michèle de Waard het politieke leven van Angela Merkel. Ze gaat in op Merkels voorbeelden, drijfveren en motieven om meteen na de val van de Muur politiek actief te worden. Discipline, strategisch inzicht en een moreel kompas zijn tekenend voor haar leiderschap. Michèle de Waard is historicus, journalist en columnist voor Het Financieele Dagblad. Ze werkte onder meer als chef Economie voor NRC Handelsblad en als Europees verslaggever en correspondent in Bonn en Berlijn. Eerder publiceerde zij Duitsland achter de schermen. Het wonder van de Berlijnse Republiek. Quote uit het boek: Op de zevende verdieping van het ‘Bundeskanzleramt’ klopt het hart van de macht. Daar is Merkels werkkamer met het moderne Adenauer- schilderij van Oskar Kokoschka aan de muur en een portret van tsarina Catharina de Grote op haar bureau dat ze ooit cadeau kreeg. Een Duitse prinses werd een van de beroemdste Russische vorstinnen, dol op het spel met de macht. Die interpretaties wuift Merkel weg. Zij bewondert haar vooral als vrouw en hervormer. – p. 166.


UvA spinoff Macrobian Biotech secures seed investment

Geplaatst op

Amsterdam, the Netherlands, Tuesday 5 September 2017- University of Amsterdam (UvA), UvA Ventures Holding BV and Innovation Exchange Amsterdam (IXA-UvA) are pooling their resources to fund Macrobian Biotech BV, a single asset biotech company that will further develop its lead compound: MB-101 for the treatment of Parkinson’s disease.

Parkinson’s disease affects 10 million people worldwide and the current therapeutic strategy is limited to dopamine supplementation with L-DOPA. The company’s underlying technology is based on pivotal findings of Dr. Lars van der Heide and Prof. Marten Smidt at the Swammerdam Institute for Life Science (SILS) at the University of Amsterdam, also the founders of this company. Macrobian Biotech’s lead compound targets endogenous dopamine production and uptake with high spatiotemporal specificity, overcoming the need for levodopa supplementation. Prof Marten Smidt, co-CEO of the company said: “The investment in Macrobian Biotech will help us accelerate our drug development program. This is a new opportunity to redefine the way Parkinson’s patients are treated.”

The spin-off company will focus on lead optimization of an undisclosed target leading up to clinical phase one, but also aims to broaden its preclinical portfolio in the coming years. To this effect, Macrobian Biotech successfully concluded its first round of financing with participation from UvA Ventures Holding. “We are delighted to join forces with IXA-UvA and FNWI in backing Macrobian Biotech. Parkinson’s disease is an enormous social and economic burden on patients and society, and we believe that this company has the potential to bring a life-changing treatment to the clinic”, explains Peter Krijnsen, CEO UvA Ventures Holding.

IXA-UvA is the valorization body of the University of Amsterdam. In addition to managing the intellectual property and extending an exclusive license to Macrobian Biotech, it has also contributed towards the seed round via its proof-of-concept fund. Dr. Mirjam Leloux, director of IXA-UvA said: “Macrobian Biotech has shown impressive technical progress over the last few years. Spun out of UvA’s SILS, we believe this investment will enable the company to develop its next generation technology and accelerate clinical development of MB-101.”

For Enquiries
Prof. Marten Smidt, CEO
Dr. Lars van der Heide, CEO
Macrobian Biotech B.V.
Tel: +31 5256479/ -706
Email: M.P.smidt@uva.nl
www.macrobian-biotech.nl


UvA-AMC-HvA Ventures Holding uitgenodigd voor de opening van de Beurs in het kader van de week van het Regionale Ondernemerschap

Geplaatst op



ACE Incubation Program: start your science or high-tech company!

Geplaatst op
Start your science or high-tech company!

Applications are now open for the ACE Incubation Program. Learn how to build your science or high-tech company with 12 weeks of training and support. We kick off on October 2nd, 2017 with a full week of workshops, followed by 11 separately organized sessions and one-on-one mentoring.

The Incubation Program is exclusively designed for MSc students, researchers & industry specialists who aim to launch & grow their innovative business. You can now apply for the Tech & Science program or sign up for a special Healthcare track via www.ace-incubator.nl . Application deadline: September 17th.

Location: Startup Village Amsterdam
For questions contact Yulia Bodnar at yulia@ace-incubator.nl

Download factsheet


AIMM signs exclusive license

Geplaatst op

AIMM signs exclusive license and option agreement with Merck & Co., Inc., Kenilworth, NJ, USA on preclinical oncology targets

AIMM Therapeutics BV, an oncology focused developer of novel tumor specific therapeutic antibodies sourced directly from elite responders to immune therapy or from immunized animals, today announced that it has entered into an exclusive license and option agreement with Merck & Co., Inc., Kenilworth, NJ, USA (known as MSD outside the United States and Canada) regarding a series of AIMM’s tumor specific antibodies directed against an undisclosed target expressed on many different tumor types. In addition, MSD has an exclusive option on a second series of AIMM’s tumor specific antibodies directed against a different tumor target.

Under the terms of the agreement between AIMM and MSD, through a subsidiary, MSD will make an undisclosed upfront payment and future success-based payments. MSD will be responsible for development, manufacturing and commercialization. Additional details were not disclosed.

“We are excited that MSD, as a leader in the field of immuno-oncology, recognizes the unique synergy and clinical potential offered by AIMM’s tumor specific antibodies in combination with KEYTRUDA® (pembrolizumab) for cancer patients who have limited or no responses to checkpoint inhibitors alone” said Jan de Vries, AIMM’s CEO.

ABOUT AIMM –Therapeutics

AIMM Therapeutics is a science driven, privately owned biotech company focused on the discovery and development of novel tumor specific antibodies for the treatment of hematological and solid tumors. Utilizing its proprietary AIMSelect platform which allows an effective immortalization of the complete B-cell repertoire, AIMM has generated a pipeline of unique antibodies from immunized non-human species including rabbits, rats and mice or from selected tumor patients who were cured and in good health after immunotherapy. AIMM has demonstrated that the cured patients, designated as “elite responders”, are a very valuable source of tumor-neutralizing antibodies. These human antibodies are thought to have contributed to the complete remissions in the patients from whom they were derived, have excellent physico-chemical characteristics and can be considered to be safe.

KEYTRUDA© is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA

AIMM Therapeutics is currently advancing two of its lead antibodies, AT1413 and AT1412 which will enter clinical development in 2018 for AML/Myelodysplastic Syndrome, and pancreatic and colon cancer respectively.
For more information: www.aimmtherapeutics.com

Contact USA: Jan de Vries: +1 858 405 1356
Contact Rest of the world: +31 20 566 2145

Contact


 

UvA Holding BV
AMC Ventures Holding BV
HvA Holding BV
Roetersstraat 35
1018 WB Amsterdam

020 - 421 0001

020 - 421 0006